openPR Logo
Press release

Dravet Syndrome Treatment Market Trends in 2019- What Industry Insiders Tell Us about the Future Forecast

Dravet Syndrome Treatment Market Trends in 2019- What Industry

MarketResearchReports.Biz announces addition of new report "Dravet Syndrome Treatment Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2018 - 2026" to its database.

Dravet syndrome is a distressing infantile-onset epilepsy, which is sometimes accompanied by severe intellectual disabilities, autistic traits, hyperactive behavior, and ataxia. Discovery of SCN1A mutation in 2001 as a primary cause of this syndrome has accelerated the knowledge of the pathophysiological processes behind Dravet syndrome. SCN1A is responsible for encoding the ?-subunit of the voltage-gated sodium channel NaV1.1. Recent studies, using genetically modified mouse models, have indicated that haploinsufficiency of NaV1.1 in GABAergic inhibitory interneurons in the forebrain may be involved in the fever sensitivity of seizures, seizure susceptibility, autistic traits, and premature death characteristics of Dravet syndrome. In recent years, human cellular models of Dravet syndrome have been recognized by the use of induced pluripotent stem cells (iPSCs) derived from patients. Functional susceptibilities in GABAergic neurons have been discovered by studying these human disease models.

Increasing R&D into new drug development for Dravet syndrome and approval for these drugs in key markets, such as, North America and Europe are anticipated to propel the development of the Dravet syndrome treatment market worldwide. For instance, in February 2018, Zogenix Inc. revealed U.S. Food and Drug Administration (FDA) approval of its Phase III drug ZX-008 for seizures associated with Dravet Syndrome. In 2017, Epygenix Therapeutics, Inc., a biopharmaceutical company, received FDA orphan drug designation for its product, EPX-300, indicated for the treatment of the Dravet syndrome. In 2017, Ovid Therapeutics (the U.S.) got orphan drug designation from FDA for its product, TAK-935/OV935. Furthermore, collaborations among key market players for the development and manufacturing of drugs indicated for the treatment of Dravet syndrome are expected to drive the growth of the Dravet syndrome treatment market, globally. For instance, in 2017, Epygenix Therapeutics, Inc. and, Laurus Synthesis Inc. entered into a strategic collaboration for the development and manufacturing of EPX-100.

Get Sample Copy of this report @

A recent U.S. epidemiology study concluded that Dravet syndrome incidence has increased to twice the previous year, affecting 1:15,700 infants, 80% of whom have an SCN1A mutation. Unfortunately, a large number of children do not get access to early diagnosis, which could have had a significant impact on long-term development and quality of life. The study concluded that genetic testing via an epilepsy panel should be considered in children with two or more prolonged seizures by the age of one year.

The Dravet syndrome treatment market can be segmented based on treatment type, distribution channel, and geography. By treatment type, the market can be divided into anticonvulsant, benzodiazepines, vagal nerve stimulation, and others. In terms of distribution channel, the marekt can be categorized into hospital pharmacies, retail pharmacies, and online pharmacies.

On the basis of geography, the global Dravet syndrome treatment market can be divided into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America held the leading share of the global Dravet syndrome treatment market in 2017, followed by Europe, due to growth initiatives and funding by various organizations to support the development of new treatment for Dravet syndrome. For instance, in 2017, Dravet Syndrome Foundation, a non-profit organization of the U.S., funded an amount of US$ 3,600,000 for the development of new treatment methods for the disorder. The Dravet syndrome treatment market in Europe is likely to exhibit significant growth during the forecast period due to increasing research and development activities conducted by key market players in the region. For instance, a British biopharmaceutical company, GW Pharmaceuticals, developed Epidiolex (cannabidiol) ingredient derived from marijuana. The company submitted a new drug application (NDA) for Epidiolex to the U.S. FDA in December 2017. After approval, the drug is expected to hit the U.S. market by mid of 2018.

Key players operating in the Dravet syndrome treatment market include Epygenix Therapeutics, Inc., GW Pharmaceuticals Plc., Ovid Therapeutics, Takeda Pharmaceutical Company Ltd, OPKO Health Inc., Zogenix, Inc, Biocodex S.A., PTC Therapeutics, Inc., and Biscayne Neurotherapeutics, Inc. Key players in the market are focusing on obtaining approval for their new drugs from major regulatory bodies, such as, FDA and European Commission.

MRR.BIZ has been compiled in-depth market research data in the report after exhaustive primary and secondary research. Our team of able, experienced in-house analysts has collated the information through personal interviews and study of industry databases, journals, and reputable paid sources.

Request For TOC Report @

The report provides the following information:

-Tailwinds and headwinds molding the market’s trajectory
-Market segments based on products, technology, and applications
-Prospects of each segment
-Overall current and possible future size of the market
-Growth pace of the market
-Competitive landscape and key players’ strategies

The main aim of the report is to:

-Enable key stakeholder’s in the market bet right on it
-Understand the opportunities and pitfalls awaiting them
-Assess the overall growth scope in the near term
-Strategize effectively with respect to production and distribution

MRR.BIZ is a leading provider of strategic market research. Our vast repository consists research reports, data books, company profiles, and regional market data sheets. We regularly update the data and analysis of a wide-ranging products and services around the world. As readers, you will have access to the latest information on almost 300 industries and their sub-segments. Both large Fortune 500 companies and SMEs have found those useful. This is because we customize our offerings keeping in mind the specific requirements of our clients.

About us is the most comprehensive collection of market research reports. MarketResearchReports.Biz services are specially designed to save time and money for our clients. We are a one stop solution for all your research needs, our main offerings are syndicated research reports, custom research, subscription access and consulting services. We serve all sizes and types of companies spanning across various industries.


Mr. Nachiket
State Tower
90 Sate Street, Suite 700
Albany, NY 12207
Tel: +1-518-621-2074

This release was published on openPR.

Permanent link to this press release:

Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Dravet Syndrome Treatment Market Trends in 2019- What Industry Insiders Tell Us about the Future Forecast here

News-ID: 1698916 • Views: 522

More Releases for Therapeutics

Dravet Syndrome Therapeutics- Pipeline Analysis 2018 | Zogenix, Inc., Ovid Thera …
Dravet syndrome is a form of severe myoclonic epilepsy that occurs in infants during their first year of age. If left untreated, it can be associated with other types of seizures, and status epilepticus. Children having Dravet syndrome are generally observed with poor cognitive skills and hyperactivity. Download the sample report @ It severely affects the person’s quality of life and around 10-20% of the patient are estimated to die due
Pontine Glioma Therapeutics- Pipeline Analysis 2018 | Y-mAbs Therapeutics, Inc.
Pontine glioma is a malignant tumour which develops from the brain stem cells. Based on the grade of growth, it is categorized into anaplastic astrocytomas and glioblastoma multiforme (GBM). Download the sample report @ Pontine glioma is more prevalent in children than adults. The common signs and symptoms of pontine glioma are squints, swallowing problems, slurred speech, facial weakness, abnormal gait, difficulty in writing and changes in personality and behaviour.
Rheumatology Therapeutics Market
Global Rheumatology Therapeutics Market: Snapshot A rising elderly population and increasing allocations for research and development of new drugs is what is serving to drive growth in the global rheumatology therapeutics market. This has led to the emergence of many new drugs. Their swift approvals by the appropriate authorities has also led to the growth in the market. A report by Transparency Market Research uncovers after in-depth study that the global rheumatology
STORM Therapeutics Joins SMi’s 9th Annual RNA Therapeutics
SMi are delighted to welcome Oliver Rausch, VP Research & Development, Storm Therapeutics, onto the speaker line-up for day 1 at RNA Therapeutics 2018! Oliver has overall responsibility for developing STORM’s target discovery platform and for the delivery of small molecule drugs from its emerging drug discovery pipeline. Oliver worked closely with scientific founders Professors Tony Kouzarides and Eric Miska to secure the initial £12m series; an investment that launched STORM
Bone Degeneration Therapeutics Market
Bone degeneration is characterized by deterioration of articular cartilage covering the joints. Cartilage aids free movement of the joint without any resistance. Reduction in flexibility of the joint due to deterioration of cartilage leads to inflammation, compressed nerves, and pain. Aging is one of the natural causes of bone degeneration, which is also fueled by several conditions such as injuries, congenital disorders, diabetes, and obesity. Symptoms of degenerative bone disorders
Global Dyslipidemia Therapeutics Market
Dyslipidemia is one of the metabolic disorder, which is described by unbalanced level and thickness of lipoproteins and triglycerides. The disorder also includes protein deficiency and over production. These disorders can be caused by increase in the serum total cholesterol, triglyceride concentrations, and low-density lipoprotein (LDL) cholesterol, and a decrease in the high-density lipoprotein (HDL) cholesterol concentration. These condition are mainly associated with cardiovascular or coronary heart disease. The other